Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve ...

New research from the University of Ottawa sees mRNA and RNAi-based therapies delivered in single treatment, paving way for treatment of cancer, cardiovascular diseases.

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting ...

We’ll also explore the company’s innovative approach to treating cancer, particularly those driven by KRAS mutations, and why Prof. Peled’s addition could be a game-changer. The recent appointment of ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

Opens in a new tab or window In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...

Researchers at the University of Ottawa have figured out how to use mRNA and RNAI-based treatments to treat complex illnesses ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

Major findings on the inner workings of a brittle star's ability to reversibly control the pliability of its tissues will ...